TOP TEN perturbations for 1552667_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552667_a_at
Selected probe(set): 226673_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552667_a_at (226673_at) across 6622 perturbations tested by GENEVESTIGATOR:

rapidly progressive glomerulonephritis; ANCA-associated vasculitis study 5 (tubulointerstitium) / focal segmental glomerulosclerosis study 9 (glomerulus)

Relative Expression (log2-ratio):-3.7672033
Number of Samples:21 / 10
Experimental rapidly progressive glomerulonephritis; ANCA-associated vasculitis study 5 (tubulointerstitium)
Tubulointerstitium tissue sample obtained by microdissection from kidney biopsy, from patients suffering from rapidly progressive glomerulonephritis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Donors were positive for ANCA-antibody. Biopsy samples were obtained from the European Renal cDNA Bank-Kroener-Fresenius biopsy bank. All biopsies were stratified by a reference pathologist.
Control focal segmental glomerulosclerosis study 9 (glomerulus)
Glomeruli tissue sample obtained by microdissection from kidney biopsy, from patients suffering from focal segmental glomerulosclerosis. Biopsy samples were obtained from the European Renal cDNA Bank-Kroener-Fresenius biopsy bank. All biopsies were stratified by a reference pathologist.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-3.3614225
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):-2.9498043
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

BMP-9 study 1 / vehicle treated blood outgrowth endothelial cell sample

Relative Expression (log2-ratio):-2.9099493
Number of Samples:3 / 4
Experimental BMP-9 study 1
Blood outgrowth endothelial cells (BOEC) treated for 4 hours with 1 ng/ml BMP9, bone morphogenetic protein 9 (in new media). Before treatment cells were kept for 12 hours in M199 media with 0.1% FBS. BOEC were generated from epithelial progenitor cells present in peripheral blood. Cells were cultured in EGM-2MV (10% FBS) and used for experiment between passages 4 and 8.
Control vehicle treated blood outgrowth endothelial cell sample
Blood outgrowth endothelial cells (BOEC) treated for 4 hours with vehicle (in new media). Before treatment cells were kept for 12 hours in M199 media with 0.1% FBS. BOEC were generated from epithelial progenitor cells present in peripheral blood. Cells were cultured in EGM-2MV (10% FBS) and used for experiment between passages 4 and 8.

Burkitt lymfoma study 4 (MAP2K inhibitor) / Burkitt lymfoma study 4 (control)

Relative Expression (log2-ratio):2.870451
Number of Samples:3 / 5
Experimental Burkitt lymfoma study 4 (MAP2K inhibitor)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment and isolated after MAP2K inhibition. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.
Control Burkitt lymfoma study 4 (control)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.

stem cell differentiation study 59 (iDRG; 15d) / stem cell differentiation study 59 (8d)

Relative Expression (log2-ratio):2.8673115
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 15d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper.
Control stem cell differentiation study 59 (8d)
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.

PMA study 3 (shRNA contr.) / mock treated / transduced Jurkat cell sample

Relative Expression (log2-ratio):2.779827
Number of Samples:2 / 2
Experimental PMA study 3 (shRNA contr.)
Jurkat cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated / transduced Jurkat cell sample
Jurkat cells were transduced with a control shRNA and then mock treated.

glioma study 17 (oligoastrocytoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):2.738081
Number of Samples:2 / 4
Experimental glioma study 17 (oligoastrocytoma; unsorted)
Brain cells isolated from low grade oligoastrocytoma (grade II). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

lung adenocarcinoma study 3 (positive) / normal lung tissue

Relative Expression (log2-ratio):-2.6369696
Number of Samples:7 / 3
Experimental lung adenocarcinoma study 3 (positive)
Primary lung adenocarcinoma samples, with bone marrow positive for early disseminated tumor cells (DTCs). The presence of DTCs can predict the subsequent occurrence of overt metastasis and survival in lung cancer.
Control normal lung tissue
Normal lung tissue.

stem cell differentiation study 59 (iDRG; 12d) / stem cell differentiation study 59 (8d)

Relative Expression (log2-ratio):2.6248846
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 12d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper.
Control stem cell differentiation study 59 (8d)
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.